Last reviewed · How we verify
JE vaccine new plant lot 2
JE vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.
JE vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus. Used for Prevention of Japanese encephalitis in endemic regions.
At a glance
| Generic name | JE vaccine new plant lot 2 |
|---|---|
| Sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
| Drug class | vaccine |
| Target | Japanese encephalitis virus envelope proteins |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated Japanese encephalitis virus antigen that triggers both humoral (antibody) and cell-mediated immune responses. This primes the immune system to recognize and neutralize the virus upon natural exposure, preventing infection or reducing disease severity. The plant-derived formulation represents a production method using plant-based expression systems rather than traditional cell culture or animal-derived sources.
Approved indications
- Prevention of Japanese encephalitis in endemic regions
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: